Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1241808

registered interest
date	08/10/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Protective Clothing: Standards
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that face coverings sold privately for use by the general public are of a high standard and effective.
tabling member constituency	Glasgow North
tabling member printed	Patrick Grady
uin	101034
answer	answer is ministerial correction date of answer 10/11/2020 answer text <p>In the United Kingdom, face coverings are being sold by a large number of retailers online and in store. Details of a product’s conformance to any standards can be found under the product details section online, or on the packaging or label of the covering itself.</p><p> </p><p>The Office for Product Safety and Standards has produced <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/899806/Guidance-for-businesses-and-individuals-face-coverings-version-3.pdf" target="_blank">guidance for manufacturers and sellers of face coverings</a>, which is available online.</p><p>In June 2020, the European Committee for Standardization (CEN) approved a Workshop Agreement with performance requirements, methods of testing and uses of community face coverings.</p><p>The British Retail Consortium has released a <a href="https://brc.org.uk/media/674992/face-coverings_guidelines_v2.pdf" target="_blank">specification for Textile Barrier Face Coverings</a> designed for both disposable and reusable coverings. The specification sets out the design, performance and chemical requirements of coverings, as well as labelling instructions.</p><p> </p><p>The British Standards Institution will not be creating a separate standard and intend to adopt the CEN Workshop Agreement. Copies of both the <a href="https://www.cen.eu/news/brief-news/Pages/NEWS-2020-004.aspx" target="_blank">CEN</a> and <a href="https://masques-barrieres.afnor.org/home/telechargement?culture=en-GB&amp;_ga=2.63895463.961209460.1593722455-599569319.1587024330" target="_blank">AFNOR</a> documents are freely available for the public to download.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 10/11/2020 11:49:37 answering member 4380 label Biography information for Jo Churchill previous answer version 54075 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4432 label Biography information for Patrick Grady

1199976

registered interest
date	03/06/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he plans to hold with his counterparts in the devolved Administrations on the findings of the Public Health England report on Disparties in the risk and outcomes of covid-19.
tabling member constituency	Glasgow North
tabling member printed	Patrick Grady
uin	54131
answer	answer is ministerial correction date of answer 18/06/2020 answer text <p>The Department is regularly in discussions with the devolved administrations at both ministerial and official level on a wide range of issues relating to COVID-19. COVID-19 presents a global challenge which requires a collaborative response. The Department will continue to work with the devolved administrations throughout the crisis and beyond.</p><p>The Parliamentary Under-Secretary of State for Equalities (Kemi Badenoch MP) will be taking forward work off the back of Public Health England’s report on disparities in the risk and outcomes of COVID-19. Stakeholder engagement will be a key part of that work, as set out in the Terms of Reference at the following link:</p><p><a href="https://www.gov.uk/government/news/next-steps-for-work-on-covid-19-disparities-announced" target="_blank">https://www.gov.uk/government/news/next-steps-for-work-on-covid-19-disparities-announced</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 18/06/2020 17:02:08 answering member 4380 label Biography information for Jo Churchill previous answer version 26745 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4432 label Biography information for Patrick Grady

1192284

registered interest
date	01/05/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using camostat mesylate in the treatment of patients with covid-19.
tabling member constituency	Glasgow North
tabling member printed	Patrick Grady
uin	42092
answer	answer is ministerial correction date of answer 15/05/2020 answer text <p>There are currently no approved treatments for COVID-19 and full evaluation of the merits of any potential treatments can only be made once clinical trials involving COVID-19 patients have been completed. The United Kingdom Government is considering a wide range of potential treatments in the current UK clinical trials. Drugs representing a range of relevant modes of action including - but not limited to - serine protease inhibitors, such as camostat, are being reviewed and prioritised by a panel of experts so that the most promising are put into clinical trials first.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 15/05/2020 11:25:11 answering member 4380 label Biography information for Jo Churchill previous answer version 19579 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4432 label Biography information for Patrick Grady